Analysts at RBC Capital Markets have predicted twice-yearly lenacapavir could become a $2 billion product, and become a key ...
Merck’s Keytruda may be the most talked about drug facing loss of exclusivity but it’s far from the only one, as several of ...
An official who oversees a team at the Food and Drug Administration that reviews Neuralink Corp. devices was fired, according to an email the agency sent to staff Tuesday morning viewed by Bloomberg.
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
About a dozen drugmakers are developing new weight-loss treatments aimed at preserving muscle, and industry analysts, ...
Doctors say drugs that improve muscle mass could benefit older or infirm people at greater risk of falls and fractures ...
Lenacapavir is a twice-yearly injectable medication designed to be used as pre-exposure prophylaxis (PrEP). The FDA is giving ...
Annie Cooper couldn't free her 5-year-old son, Thomas, from a hyperbaric chamber as flames engulfed him last month. Her ...
Vimkunya is supplied as an injectable suspension; the vaccine is administered intramuscularly as a single 0.8mL dose.
The U.S. Food and Drug Administration has approved Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) for acti ...
We assign Siegfried a Medium Morningstar Uncertainty Rating. Its business is relatively stable, with high switching costs and good visibility due to long-term customer contracts. However, small ...
The Trump administration is tearing down both regulations and the federal government that enforces them. The consequences will be enormous.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback